Table 1.
ADC drugs
| Drug | Target spot | Stage | Number | Identifier |
|---|---|---|---|---|
| Sacrituzumab | TROP-2 | II | 51 | NCT04230109 |
| Govitecan | ||||
| Datopotamab | TROP-2 | I | NCT03401385 | |
| Deruxtecan | II | 118 | NCT05460273 | |
| PF-06664178 | TROP-2 | I | 31 | NCT02122146 |
| ZEN003694 | I | 75 | NCT02711956 | |
| Talazoparib | TROP-2 | II | 179 | NCT03901469 |
| SKB264 | TROP-2 | I/II | 430 | NCT04152499 |
| Enfortumab Vedotin | Nectin-4 | II | 288 | NCT04225117 |
| PF-06650808 | Notch3 | I | 40 | NCT02129205 |
| PF-06647263 | I | 60 | NCT02078752 | |
| PF-06647020 | I | 138 | NCT02222922 | |
| PF-06263507 | I | 26 | NCT01891669 | |
| BAY94-9343 | I | 12 | NCT02485119 | |
| Cofetuzumab Pelidotin | PTK7 | I | 18 | NCT03243331 |
| AVID100 | I | 49 | NCT01891669 | |
| CAB-RC48-ADC | EGFR | I/II | 49 | NCT01891669 |
| SAR566658 | Ror2 | I/II | 420 | NCT03504488 |
| RC48-ADC | CA6 | II | 23 | NCT02984683 |
| RC108 | II | 64 | NCT05331326 | |
| SKB264 | I | 32 | NCT05331326 | |
| MRG002 | II | 95 | NCT05445908 | |
| ARX788 | II | 66 | NCT04742153 | |
| DS-8201a | I | 106 | NCT03255070 | |
| ADCT-502 | I | 75 | NCT03366428 | |
| ADCT-301 | HER-2 | I | 21 | NCT03125200 |
| PF-06804103 | I | 78 | NCT03621982 | |
| A166 | HER-2 | 95 | NCT03284723 | |
| XB002 | I/II | 49 | NCT03602079 | |
| BAY94-9343 | I | 524 | NCT04925284 | |
| TORL-2-307-ADC | I | 12 | NCT02485119 | |
| TORL-1-23 | I | 70 | NCT05156866 | |
| CAB-AXL-ADC | I | 70 | NCT05103683 | |
| FDA018-ADC | II | 240 | NCT05103683 | |
| TR1801-ADC | I | 78 | NCT05174637 | |
| F0002-ADC | I | 40 | NCT03859752 | |
| OBT076 | I | 23 | NCT03894150 | |
| HS-20089 | I | 150 | NCT04064359 | |
| STRO-002 | I | 177 | NCT05263479 | |
| FOR46 | I | 160 | NCT03748186 | |
| MYTX-011 | I | 56 | NCT03575819 | |
| SYD1875 | I | 150 | NCT05652868 | |
| REGN5093-M114 | I | 31 | NCT04202705 | |
| SOT102 | I/II | 81 | NCT04982224 | |
| STI-6129 | I/II | 269 | NCT05525286 | |
| FDA022-BB05 | I/II | 64 | NCT05565807 | |
| I | 107 | NCT05564858 |